Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATZUMI vs STELAZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with PD-L1 expression ≥50%, with no EGFR or ALK genomic aberrations,First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide,First-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic aberrations, in combination with bevacizumab, paclitaxel, and carboplatin,First-line treatment of metastatic squamous NSCLC in combination with paclitaxel and carboplatin,Treatment of locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, or in cisplatin-ineligible patients with PD-L1 expression,Treatment of metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (d MMR) after prior fluoropyrimidine, oxaliplatin, and irinotecan therapy,Off-label uses: Various solid tumors with PD-L1 expression or MSI-H/d MMR
Schizophrenia,Short-term treatment of generalized non-psychotic anxiety (off-label)
1.2 g intravenously every 12 hours over 10-12 hours.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
Terminal elimination half-life is 12-15 hours in patients with normal renal function (Cr Cl >90 m L/min), allowing once-daily dosing. Renal impairment prolongs half-life (up to 30 hours in Cr Cl 30-50 m L/min).
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Metabolized via catabolic pathways into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Hepatic via CYP450 enzymes (primarily CYP2D6); also undergoes N-demethylation and sulfoxidation.
Approximately 70% of the dose is excreted renally as unchanged drug; 20% is eliminated via biliary/fecal routes as metabolites, with <5% as unchanged drug in feces.
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
95% bound to albumin and alpha-1-acid glycoprotein; binding is saturable at high concentrations.
92-97% bound to albumin and alpha-1 acid glycoprotein.
2.5-3.5 L/kg, indicating extensive extravascular distribution (e.g., tissues, erythrocytes).
Approximately 18-30 L/kg (0.5-1.5 L/kg). Clinical meaning: Extensive tissue distribution with high CNS penetration.
Oral: 70-80% (first-pass metabolism reduces bioavailability; food increases absorption by 15%).
Oral: ~40% (due to first-pass metabolism); IM: 100%.
Cr Cl 30-60 m L/min: 1.2 g every 18 hours; Cr Cl 10-29 m L/min: 1.2 g every 24 hours; Cr Cl <10 m L/min: 1.2 g loading dose then 0.6 g every 24 hours.
No specific dose adjustment recommended; use caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use or reduce dose by 75%.
Not approved for pediatric patients under 18 years.
Children 6-12 years: 1 mg 1-2 times daily; increase gradually up to 15 mg/day. Children >12 years: adult dosing.
No specific dose adjustment required; monitor renal function.
Initiate at 1-2 mg twice daily; titrate slowly due to increased sensitivity and risk of orthostatic hypotension and extrapyramidal symptoms.
None.
Increased mortality in elderly patients with dementia-related psychosis.
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin adverse reactions,Infusion-related reactions,Embryofetal toxicity,Increased risk of severe or fatal infection,Use caution in patients with autoimmune disease or organ transplant
Tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation, leukopenia/neutropenia/agranulocytosis, seizure threshold lowering, anticholinergic effects, hypotension, cholestatic jaundice, ocular changes (corneal/lenticular deposits).
Severe hypersensitivity to atzumi or any excipients,Active severe autoimmune disease requiring systemic immunosuppression (relative),Pregnancy (embryofetal toxicity)
Comatose states, CNS depression (e.g., barbiturates, alcohol), bone marrow depression, blood dyscrasias, hepatic disease, hypersensitivity to phenothiazines.
Avoid alcohol consumption during therapy and for 48 hours after last dose due to risk of disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions known.
Avoid alcohol and CNS depressants. Grapefruit juice may increase drug levels; avoid concurrent use. Limit caffeine intake. No specific dietary restrictions, but monitor weight gain due to increased appetite.
Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avoid unless benefit outweighs risk.
First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimesters: Risk of extrapyramidal symptoms, jaundice, and hyperreflexia in neonates with late exposure. Case reports of neonatal withdrawal and EPS. Not a known major teratogen but use only if benefits outweigh risks.
No data on excretion in human milk; M/P ratio unknown. Caution advised; use only if clearly needed.
Excreted in breast milk in small amounts; relative infant dose est. ~0.1-0.5% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, EPS, and poor feeding. Generally considered compatible with breastfeeding with caution.
No established dosing adjustments; pharmacokinetic changes in pregnancy may alter exposure. Monitor therapeutic response and adjust dose empirically based on clinical efficacy and toxicity.
Increased clearance in pregnancy may necessitate dose titration. Start at low end of dosing range; increase gradually based on response and tolerability. Monitor for relapse. Postpartum dose may need reduction due to restored clearance. No specific PK studies available; clinical judgment advised.
ATZUMI (aztreonam) is a monobactam antibiotic with activity against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. It is often used in patients with severe beta-lactam allergies (e.g., anaphylaxis to penicillins) due to minimal cross-reactivity. Monitor renal function (creatinine clearance) as dose adjustment is required in renal impairment. For cystic fibrosis patients, higher doses or continuous infusion may be considered. Administer over 20-60 minutes to reduce infusion-related phlebitis. Note: Inhaled aztreonam lysine (not ATZUMI) is used for chronic pulmonary infections in cystic fibrosis.
Extrapyramidal symptoms (EPS) are common; use benztropine prophylactically in young males. Monitor for QT prolongation, especially in elderly. Avoid in patients with history of tardive dyskinesia. Can cause orthostatic hypotension; titrate slowly. Neuroleptic malignant syndrome (NMS) rare but serious; discontinue immediately if hyperthermia, rigidity, autonomic instability occur.
Take this medication exactly as prescribed; do not skip doses or stop early unless instructed.,Report any signs of allergic reaction (rash, hives, itching, difficulty breathing, swelling of face/tongue) immediately.,Infusion site reactions (redness, swelling, pain) are common; notify healthcare provider if severe.,This drug may cause diarrhea, especially if prolonged; contact your doctor if watery or bloody stools occur.,Avoid alcohol while on this medication to reduce risk of disulfiram-like reaction (nausea, vomiting, headache).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Complete full course even if you feel better to prevent antibiotic resistance.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness upon standing; rise slowly from sitting or lying down.,Report any involuntary muscle movements, stiffness, or tremors to your doctor.,Avoid alcohol and other central nervous system depressants.,May cause drowsiness; use caution when driving or operating machinery.,Notify your doctor if you experience rapid heartbeat, fainting, or fever with muscle rigidity.,Avoid exposure to extreme heat (can impair body temperature regulation).,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATZUMI vs STELAZINE, answered by our medical review team.
ATZUMI is a Benzodiazepine Anticonvulsant that works by Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.. STELAZINE is a Phenothiazine Antipsychotic that works by Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATZUMI and STELAZINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATZUMI is: 1.2 g intravenously every 12 hours over 10-12 hours.. The standard adult dose of STELAZINE is: Adults: 2-10 mg orally twice daily; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATZUMI and STELAZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATZUMI is classified as Category C. Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avo. STELAZINE is classified as Category C. First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimester. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.